plicamycin has been researched along with lbw242 in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Belka, C; Daniel, PT; Essmann, F; Gillissen, B; Hemmati, PG; Overkamp, T; Preissner, R; Richter, A | 1 |
1 other study(ies) available for plicamycin and lbw242
Article | Year |
---|---|
Targeted therapy of the XIAP/proteasome pathway overcomes TRAIL-resistance in carcinoma by switching apoptosis signaling to a Bax/Bak-independent 'type I' mode.
Topics: Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Carcinoma; Caspase 3; Caspase 8; Colonic Neoplasms; Drug Resistance, Neoplasm; HCT116 Cells; Humans; Oligopeptides; Plicamycin; Proteasome Endopeptidase Complex; RNA Interference; RNA, Small Interfering; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; X-Linked Inhibitor of Apoptosis Protein | 2013 |